- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02591732
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments.
Furthermore to describe persistence to each OAT and risk of bleeding after initiating each OAT.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Hellerup, Dinamarca, 2900
- Local Institution
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
The study population will consist of all patients in Denmark who meet the following criteria:
- Adult (≥18 years) at time of anticoagulant initiation
- Diagnosed with atrial fibrillation without recorded valvular disease
- Initiated a new OAT during the study period (January 1, 2011 and December 31, 2014).
- For the identification of NVAF cases, the appearance at least one hospital discharge diagnosis of AF will be searched in the databases.
Exclusion Criteria:
- Patients with prosthetic heart valves , rheumatic mitral or aortic valve disorders, and mitral aortic stenosis will be excluded
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
---|
Paciente tratado com Apixabana
|
Paciente tratado com Rivaroxabana
|
Paciente tratado com Dabigatrana
|
Paciente tratado com antagonistas da vitamina K
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
The sociodemographic characteristics of all patients with nonvalvular atrial fibrillation (NVAF) who initiated an OAT based on data available in Danish National Patient Registry
Prazo: Approximately 4 years
|
Sociodemographic characteristics: Age,sex, ethnicity, region of residence, education, income and employment status
|
Approximately 4 years
|
Clinical characteristics of all patients with NVAF who initiated an Oral anticoagulant therapy (OAT) based on data available in Danish National Patient Registry
Prazo: Approximately 4 years
|
Clinical characteristics: Myocardial infarction, Stroke, Thromboembolism, Hypertension, Peripheral artery disease, Congestive cardiac failure
|
Approximately 4 years
|
Previous Oral anticoagulant therapy of all patients with NVAF who initiated an OAT based on data available in Danish National Patient Registry
Prazo: Approximately 4 years
|
Oral anticoagulant: Apixaban, Dabigatran, Rivaroxaban and Vitamin K antagonist
|
Approximately 4 years
|
Concomitant medications of all patients with NVAF who initiated an OAT based on data available in Danish National Patient Registry
Prazo: Approximately 4 years
|
Concomitant medication Drug classes: Anti-arrhythmic agents, Antidiabetic agents, Antihypertensive agents, Proton pump inhibitors
|
Approximately 4 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Persistence to each OAT after initiation as monotherapy
Prazo: Approximately 4 years
|
Persistence will be defined as treatment discontinuation and will be measured by estimating the following: Discontinuation - the absence of any delivery of this product and of any other anticoagulation therapy of interest for 30 days. The date of discontinuation the OAT will be determined according to predefined algorithms to calculate treatment duration in the national prescription registry. Sensitivity analysis including a 30 and 60 day grace period will be performed to take into account incomplete adherence to treatment and dose modifications |
Approximately 4 years
|
Persistence between apixaban and other OAT
Prazo: Approximately 4 years
|
Oral anticoagulant: Dabigatran, Rivaroxaban and Vitamin K antagonist
|
Approximately 4 years
|
Clinically relevant bleeding events after initiating an OAT as monotherapy
Prazo: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring hospitalization in patients treated with apixaban
Prazo: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring out-patient care in patients treated with apixaban
Prazo: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring hospitalization in patients treated with rivaroxaban
Prazo: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring out-patient care in patients treated with rivaroxaban
Prazo: Approximately 4 years
|
Approximately 4 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CV185-377
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .